Cemdisiran, an investigational small interfering RNA (siRNA) therapeutic targeting complement component 5 (C5), led to fewer ...

An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase ...

Gastroenterologist Joseph Salhab, DO, shared his top ten natural laxatives to aid with regular bowel movements. Meanwhile, ...

Starting a GLP-1 receptor agonist after giving birth is becoming more common, an analysis of claims data showed. The ...

"Statements suggesting AI is inherently better informed than physicians, or that physicians cannot be trusted to make ...

A woman on death row in Tennessee survived two doses of lethal injection before her execution was called off. (The Hill) ...

Three Republican states went to the Supreme Court on Wednesday to challenge abortion "shield laws" protecting providers in ...

Users of GLP-1 receptor agonists had as much as fourfold higher likelihood for nail disorders, particularly onycholysis (separation of the fingernails or toenails), compared with patients not taking ...

The FDA expanded its approval of mavacamten (Camzyos) to include children with symptomatic obstructive hypertrophic ...

Adults with type 2 diabetes achieved impressive weight loss with an investigational combination agent of eloralintide plus ...

Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies ...